Document is current
Any future updates will be listed below
-
Authors
Lindland, Elisabeth S. https://orcid.org/0000-0001-8900-4419
Røvang, Martin S. https://orcid.org/0000-0002-8890-1561
Solheim, Anne Marit https://orcid.org/0000-0001-7357-6287
Andreassen, Silje https://orcid.org/0000-0003-1668-5799
Skarstein, Ingerid https://orcid.org/0009-0006-3221-3643
Dareez, Nazeer https://orcid.org/0000-0002-7258-3693
MacIntosh, Bradley J. https://orcid.org/0000-0001-7300-2355
Eikeland, Randi https://orcid.org/0000-0003-0104-9626
Ljøstad, Unn https://orcid.org/0000-0002-7666-1396
Mygland, Åse https://orcid.org/0000-0001-9160-2805
Bos, Steffan D. https://orcid.org/0000-0002-2975-7520
Ulvestad, Elling https://orcid.org/0000-0001-5901-8422
Reiso, Harald https://orcid.org/0000-0003-4874-8707
Lorentzen, Åslaug R. https://orcid.org/0000-0002-6918-4157
Harbo, Hanne F. https://orcid.org/0000-0002-6047-0122
Bjørnerud, Atle https://orcid.org/0000-0002-3486-3141
Beyer, Mona K. https://orcid.org/0000-0001-9156-6357
-
Funding
Funding for this research was provided by:
Sørlandet Sykehus HF
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 2 October 2024
First Online: 18 October 2024
Declarations
:
: The study was approved by the regional ethical committee and data protection service (South-Eastern Norway Health Authority 2015/1588), and was performed in line with the principles of the Declaration of Helsinki.
: Participants gave written informed consent.
: Mona K. Beyer received minor grants or speaker´s fees from Biogen Idec, Merck and Novartis. Hanne F. Harbo received minor grants or speaker´s fees from Biogen, Sanofi Genzyme, Teva and Merck. Åslaug R. Lorentzen received minor grant from Sanofi. The other authors do not report any disclosures.
